Adding cancer antigen 125 screening to gray scale sonography for predicting specific diagnosis of benign adnexal masses in premenopausal women: is it worthwhile?

Juan Luis Alcázar, S. Guerriero, Stefano Guerriero, José Ángel Mínguez, S. Ajossa, Silvia Ajossa, Anna Maria Paoletti, Alvaro Ruiz-Zambrana, Álvaro Ruiz-Zambrana, M. Jurado, Matías Jurado
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2011 · vol. 30(10) , pp. 1381–1386 · doi:10.7863/jum.2011.30.10.1381 · PMID:21968488 · W1935948634
Other OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Adding CA-125 screening to sonography did not improve specific diagnosis of benign adnexal masses, except for endometriomas, where it significantly increased diagnostic probability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: The purpose of this study was to assess whether a single determination of the serum cancer antigen 125 (CA-125) level provides additional information to sonography for specific diagnosis of benign adnexal masses in premenopausal women. METHODS: We conducted a retrospective study comprising 1058 premenopausal women (mean age, 34.8 years) with histologically proven benign adnexal masses. All women had undergone transvaginal sonography and serum CA-125 determination within 1 week before surgery and tumor removal. According to "pattern recognition" analysis, a presumptive diagnosis was provided on gray scale transvaginal sonography for all masses. Positive and negative likelihood ratios were calculated for gray scale sonography and gray scale sonography plus CA-125. RESULTS: Eighty-five women had bilateral masses (1143 masses analyzed). In 7 women with bilateral masses, the histologic diagnoses of the masses were discordant and were excluded. Histologic diagnoses were as follows: endometrioma, n = 452; dermoid cyst, n = 180; serous cyst, n = 158; hemorrhagic cyst, n = 119; mucinous cyst, n = 54; hydrosalpinx, n = 37; and other, n = 109. The median CA-125 level was significantly higher in endometrioma (71.9 IU/mL; range: 5-2620 IU/mL) and hydrosalpinx (59.2 IU/mL; range, 5-601 IU/mL) compared to all other tumor types (P < .001). The CA-125 level was 35 IU/mL or higher in 74% of endometriomas, 58% of hydrosalpinges, 34% of hemorrhagic cysts, 18% of mucinous cysts, 14% of dermoid cysts, and 8% of serous cysts. The positive and negative likelihood ratios for sonography and sonography plus CA-125 (335 IU/mL) for each kind of tumor were not statistically different except for endometrioma, for which the positive likelihood ratio for sonography plus CA-125 (55.0; 95% confidence interval, 27.5-109.9) was significantly higher than for sonography alone (19.2; 95% confidence interval, 13.6-27.1). CONCLUSIONS: Cancer antigen 125 screening does not add useful information for specific diagnosis of benign adnexal tumors, except for endometrioma. An elevated CA-125 level significantly increases the probability of such a lesion.

My notes (saved in your browser only)

Condition tags

endometrioma

MeSH descriptors

Adnexal Diseases CA-125 Antigen Adnexal Diseases Adnexal Diseases Adolescent Adult Biomarkers, Tumor Biomarkers, Tumor CA-125 Antigen Chi-Square Distribution Confidence Intervals Female Humans Likelihood Functions Middle Aged Pattern Recognition, Automated Predictive Value of Tests Premenopause Retrospective Studies Statistics, Nonparametric

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (21)

Cited by (4)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T21:09:27.188120+00:00
unpaywall
last seen: 2026-10-09T06:36:44.367587+00:00
License: CC0 · commercial use OK